or Try an Advanced Search...

    Stage Biopharmaceutical Stocks List

    Symbol Grade Name % Change
    ABVC F ABVC Biopharma, Inc. 0.93
    ACXP F Acurx Pharmaceuticals, Inc. -0.89
    ALGS F Aligos Therapeutics, Inc. -2.53
    ASND D Ascendis Pharma A/S -0.04
    AVTE D Aerovate Therapeutics, Inc. -1.94
    AXSM D Axsome Therapeutics, Inc. 1.36
    CADL B Candel Therapeutics, Inc. 4.17
    CLRB D Cellectar Biosciences, Inc. -4.24
    CRBP B Corbus Pharmaceuticals Holdings, Inc. 7.89
    CRVS C Corvus Pharmaceuticals, Inc. -0.44
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - General
    Related Stock Lists: Medicine Clinical Medicine Cancer Biotechnology Cancer Immunotherapy Chemotherapy Depression Hypertension Life Sciences Organ Systems Pancreatic Cancer Pulmonary Arterial Hypertension Radiation Adenosine Advanced Solid Tumors Ajulemic Acid Alcohol Alzheimer's Disease Antibiotics Antidepressants

    Related ETFs - A few ETFs which own one or more of the above listed Stage Biopharmaceutical stocks.

    Symbol Grade Name Weight
    MEDI D Harbor Health Care ETF 16.82
    XPH D SPDR S&P Pharmaceuticals ETF 4.95
    BBP C BioShares Biotechnology Products Fund 4.16
    PILL F Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF 3.89
    SYNB B Putnam BioRevolution ETF 3.8
    View all Stage Biopharmaceutical ETFs...
    Compare ETFs
    Compare MEDI to PILL Compare XPH to BBP Compare XPH to SYNB

        Stage Biopharmaceutical Stocks Recent News

        Date Stock Title
        May 20 CLRB Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
        May 20 CADL Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
        May 18 AXSM 3 Monster Stocks in the Making You Can Buy Right Now
        May 16 ALGS After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
        May 16 ACXP Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...
        May 16 ACXP Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
        May 15 ASND FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
        May 15 ACXP Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript
        May 15 ASND FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
        May 15 ABVC Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
        May 15 ACXP Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
        May 15 ACXP Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
        May 15 ACXP Acurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04
        May 15 CLRB Q1 2024 Cellectar Biosciences Inc Earnings Call
        May 15 CLRB Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
        May 14 ASND US Equity Markets Close Higher Tuesday as Producer Prices Rise
        May 14 ASND Ascendis Pharma says FDA has delayed TransCon PTH review
        May 14 ASND UPDATE 1-FDA extends review of Ascendis Pharma's hormone disorder therapy
        May 14 CADL Candel Therapeutics GAAP EPS of -$0.28
        May 14 ASND Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
        Related Industries: Biotechnology Drug Manufacturers - General
        Related Stock Lists: Medicine Clinical Medicine Cancer Biotechnology Cancer Immunotherapy Chemotherapy Depression Hypertension Life Sciences Organ Systems Pancreatic Cancer Pulmonary Arterial Hypertension Radiation Adenosine Advanced Solid Tumors Ajulemic Acid Alcohol Alzheimer's Disease Antibiotics Antidepressants
        Stage Biopharmaceutical

        Browse All Tags